CPSA’s office is closed from noon on Dec. 24, 2025, through Jan. 1, 2026, reopening at 8:15 a.m. on Jan. 2, 2026. For urgent requests unrelated to annual renewal, call 1-800-561-3899. For annual renewal and all other inquiries, email support@cpsa.ca and we will respond when our office reopens. More information
Back to All FAQs

Do I need to register with TPP Alberta in order to prescribe buprenorphine/naloxone?

Posted June 4, 2020

No. As of July 2019, when buprenorphine/naloxone was changed to Type 2 TPP Alberta status, registration with the Program was no longer required.  Use of the secure TPP Alberta secure form is no longer required when prescribing buprenorphine/naloxone combination products.  Single-entity buprenorphine products continue to be  TPP Type 1 category so registration with TPP Alberta and use of the secure pad are required.

Innovation at CPSA

We are the only medical regulator in Canada with an in-house Analytics, Innovation & Research (AIR) team. Learn how CPSA's regulatory-based research supports quality medical practice.